Targeting PRAME for acute myeloid leukemia therapy

被引：3
作者：
Yang, Jinjun [1 ,2 ]
Chen, Mengran [1 ,2 ]
Ye, Jing [3 ,4 ]
Ma, Hongbing [1 ,2 ]
机构：
[1] Sichuan Univ, West China Hosp, Inst Hematol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Inst Hematol, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Dermatol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词：
PRAME; acute myeloid leukemia; leukemia-associated antigen; minimal residual disease; immunotherapy; adoptive T-cell therapy; MINIMAL RESIDUAL DISEASE; PREFERENTIALLY EXPRESSED ANTIGEN; MESSENGER-RNA EXPRESSION; CANCER-TESTIS ANTIGENS; CYTOTOXIC T-CELLS; RETINOIC ACID; IN-VITRO; GENE-EXPRESSION; MELANOMA PRAME; PERIPHERAL-BLOOD;
D O I：
10.3389/fimmu.2024.1378277
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Despite significant progress in targeted therapy for acute myeloid leukemia (AML), clinical outcomes are disappointing for elderly patients, patients with less fit disease characteristics, and patients with adverse disease risk characteristics. Over the past 10 years, adaptive T-cell immunotherapy has been recognized as a strategy for treating various malignant tumors. However, it has faced significant challenges in AML, primarily because myeloid blasts do not contain unique surface antigens. The preferentially expressed antigen in melanoma (PRAME), a cancer-testis antigen, is abnormally expressed in AML and does not exist in normal hematopoietic cells. Accumulating evidence has demonstrated that PRAME is a useful target for treating AML. This paper reviews the structure and function of PRAME, its effects on normal cells and AML blasts, its implications in prognosis and follow-up, and its use in antigen-specific immunotherapy for AML.
引用
收藏
页数：13
相关论文
共 114 条
[1]   Preliminary analysis of a phase 1/2 study of NEXI-001 donor-derived multi-antigen-specific CD8+ T-cells for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT). [J].
Al Malki, Monzr ;
Vasu, Sumithira ;
Modi, Dipenkumar ;
Perales, Miguel-Angel ;
Bui, Donna ;
Edavana, Vineetha ;
Kim, Sojung ;
Suarez, Lauren ;
Oelke, Mathias ;
Bednarik, Dan ;
Knight, Robert D. ;
Varela, Juan Carlos .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2]   Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? [J].
Al-Khadairi, Ghaneya ;
Decock, Julie .
CANCERS, 2019, 11 (07)
[3]   PRAME-Specific Allo-HLA-Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer [J].
Amir, Avital L. ;
van der Steen, Dirk M. ;
van Loenen, Marleen M. ;
Hagedoorn, Renate S. ;
de Boer, Renate ;
Kester, Michel D. G. ;
de Ru, Arnoud H. ;
Lugthart, Gert-Jan ;
van Kooten, Cees ;
Hiemstra, Pieter S. ;
Jedema, Inge ;
Griffioen, Marieke ;
van Veelen, Peter A. ;
Falkenburg, J. H. Frederik ;
Heemskerk, Mirjam H. M. .
CLINICAL CANCER RESEARCH, 2011, 17 (17) :5615-5625
[4]  
Andrade Valeria C C, 2008, Cancer Immun, V8, P2
[5]   Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia [J].
Atanackovic, Djordje ;
Luetkens, Tim ;
Kloth, Benjamin ;
Fuchs, Gregor ;
Cao, Yanran ;
Hildebrandt, York ;
Meyer, Sabrina ;
Bartels, Katrin ;
Reinhard, Henrike ;
Lajmi, Nesrine ;
Hegewisch-Becker, Susanna ;
Schilling, Georgia ;
Platzbecker, Uwe ;
Kobbe, Guido ;
Schroeder, Thomas ;
Bokemeyer, Carsten ;
Kroeger, Nicolaus .
AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (11) :918-922
[6]   Understanding and harnessing the graft-versus-leukaemia effect [J].
Barrett, A. John .
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (06) :877-888
[7]   The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia [J].
Bewersdorf, Jan Philipp ;
Shallis, Rory M. ;
Boddu, Prajwal C. ;
Wood, Brent ;
Radich, Jerald ;
Halene, Stephanie ;
Zeidan, Amer M. .
BLOOD REVIEWS, 2020, 43
[8]   Recent advances in targeted therapies in acute myeloid leukemia [J].
Bhansali, Rahul S. S. ;
Pratz, Keith W. W. ;
Lai, Catherine .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
[9]   Duplication and positive selection among hominin-specific PRAME genes [J].
Birtle Z. ;
Goodstadt L. ;
Ponting C. .
BMC Genomics, 6 (1)
[10]   Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia [J].
Bullinger, L ;
Döhner, K ;
Bair, E ;
Fröhling, S ;
Schlenk, RF ;
Tibshirani, R ;
Döhner, H ;
Pollack, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) :1605-1616
12345678910